Interesting to note that of the 20 patients treated, 5 had EMD and of the 6 responses to treatment, 3 of them were EMD.
I view this presentation as highly encouraging, hopefully we can start treating healthier patients with RC220 sooner rather than later. RAC appears to have a product that works, that's more than half the battle won.
Best of luck and congratulations to Prof Nagler and the team at Sheba.
ASH2023 - Sheba 2.0, page-5
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
-0.055(3.79%) |
Mkt cap ! $237.8M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.45 | $1.33 | $213.7K | 155.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 55 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 7167 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |